Log in

Tandem Diabetes Care Stock Price, News & Analysis (NASDAQ:TNDM)

$63.58
+0.55 (+0.87 %)
(As of 10/18/2019 04:00 PM ET)
Today's Range
$62.10
Now: $63.58
$64.94
50-Day Range
$53.83
MA: $62.12
$73.01
52-Week Range
$26.40
Now: $63.58
$74.81
Volume1.27 million shs
Average Volume1.26 million shs
Market Capitalization$3.73 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.19
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 Insulin Delivery System with Basal-IQ Technology; t:slim X2 with G5 Integration; and Tandem Device Updater that allows users to update their pump's software. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TNDM
CUSIPN/A
Phone858-366-6900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$183.87 million
Book Value$2.29 per share

Profitability

Net Income$-122,610,000.00

Miscellaneous

Employees653
Market Cap$3.73 billion
Next Earnings Date11/4/2019 (Confirmed)
OptionableOptionable

Receive TNDM News and Ratings via Email

Sign-up to receive the latest news and ratings for TNDM and its competitors with MarketBeat's FREE daily newsletter.


Tandem Diabetes Care (NASDAQ:TNDM) Frequently Asked Questions

What is Tandem Diabetes Care's stock symbol?

Tandem Diabetes Care trades on the NASDAQ under the ticker symbol "TNDM."

When did Tandem Diabetes Care's stock split? How did Tandem Diabetes Care's stock split work?

Shares of Tandem Diabetes Care reverse split on Tuesday, October 10th 2017. The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 9th 2017. An investor that had 100 shares of Tandem Diabetes Care stock prior to the reverse split would have 10 shares after the split.

How were Tandem Diabetes Care's earnings last quarter?

Tandem Diabetes Care Inc (NASDAQ:TNDM) announced its quarterly earnings data on Thursday, August, 1st. The medical device company reported ($0.03) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.23) by $0.20. The medical device company had revenue of $93.26 million for the quarter, compared to analyst estimates of $69.95 million. Tandem Diabetes Care had a negative return on equity of 19.31% and a negative net margin of 19.55%. The company's revenue for the quarter was up 173.2% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.33) EPS. View Tandem Diabetes Care's Earnings History.

When is Tandem Diabetes Care's next earnings date?

Tandem Diabetes Care is scheduled to release their next quarterly earnings announcement on Monday, November 4th 2019. View Earnings Estimates for Tandem Diabetes Care.

How can I listen to Tandem Diabetes Care's earnings call?

Tandem Diabetes Care will be holding an earnings conference call on Monday, November 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has Tandem Diabetes Care issued on next quarter's earnings?

Tandem Diabetes Care issued an update on its FY 2019 earnings guidance on Thursday, August, 1st. The company provided EPS guidance of for the period. The company issued revenue guidance of $350-365 million, compared to the consensus revenue estimate of $312.78 million.

What price target have analysts set for TNDM?

13 brokers have issued 1 year target prices for Tandem Diabetes Care's shares. Their forecasts range from $55.00 to $100.00. On average, they expect Tandem Diabetes Care's share price to reach $75.31 in the next year. This suggests a possible upside of 18.4% from the stock's current price. View Analyst Price Targets for Tandem Diabetes Care.

What is the consensus analysts' recommendation for Tandem Diabetes Care?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tandem Diabetes Care.

Has Tandem Diabetes Care been receiving favorable news coverage?

Press coverage about TNDM stock has been trending somewhat negative recently, InfoTrie Sentiment reports. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Tandem Diabetes Care earned a news sentiment score of -1.5 on InfoTrie's scale. They also assigned media coverage about the medical device company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Tandem Diabetes Care.

Are investors shorting Tandem Diabetes Care?

Tandem Diabetes Care saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 5,170,000 shares, an increase of 10.9% from the August 30th total of 4,660,000 shares. Based on an average daily volume of 1,280,000 shares, the short-interest ratio is presently 4.0 days. Currently, 9.6% of the company's shares are sold short. View Tandem Diabetes Care's Current Options Chain.

Who are some of Tandem Diabetes Care's key competitors?

What other stocks do shareholders of Tandem Diabetes Care own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tandem Diabetes Care investors own include Verizon Communications (VZ), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), HCA Healthcare (HCA), Pandora Media (P), Ryder System (R), Paypal (PYPL) and Tesla (TSLA).

Who are Tandem Diabetes Care's key executives?

Tandem Diabetes Care's management team includes the folowing people:
  • Mr. Kim D. Blickenstaff, Exec. Chairman (Age 67)
  • Mr. John F. Sheridan, Pres & CEO (Age 64)
  • Mr. Brian B. Hansen, Exec. VP & Chief Commercial Officer (Age 51)
  • Ms. Leigh A. Vosseller, Exec. VP, CFO & Treasurer (Age 46)
  • Mr. Manuel Jaime, Sr. VP of Technology & Digital Health

Who are Tandem Diabetes Care's major shareholders?

Tandem Diabetes Care's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Stephens Investment Management Group LLC (0.85%), Coastal Investment Advisors Inc. (0.04%), First Hawaiian Bank (0.01%), Wedbush Securities Inc. (0.01%), Tuttle Tactical Management (0.01%) and Zurcher Kantonalbank Zurich Cantonalbank (0.01%). Company insiders that own Tandem Diabetes Care stock include Brian B Hansen, Christopher J Twomey, David B Berger, Dick Allen, Douglas A Roeder, Edward L Cahill, Howard E Greene Jr, John F Sheridan, Kim D Blickenstaff, Leigh Vosseller, Richard P Valencia and Susan Morrison. View Institutional Ownership Trends for Tandem Diabetes Care.

Which major investors are selling Tandem Diabetes Care stock?

TNDM stock was sold by a variety of institutional investors in the last quarter, including Meeder Asset Management Inc. and Wedbush Securities Inc.. Company insiders that have sold Tandem Diabetes Care company stock in the last year include Brian B Hansen, David B Berger, Dick Allen, Douglas A Roeder, Edward L Cahill, Howard E Greene Jr, John F Sheridan, Kim D Blickenstaff, Leigh Vosseller and Susan Morrison. View Insider Buying and Selling for Tandem Diabetes Care.

Which major investors are buying Tandem Diabetes Care stock?

TNDM stock was bought by a variety of institutional investors in the last quarter, including Stephens Investment Management Group LLC, First Hawaiian Bank, Coastal Investment Advisors Inc., Tuttle Tactical Management and Zurcher Kantonalbank Zurich Cantonalbank . Company insiders that have bought Tandem Diabetes Care stock in the last two years include Christopher J Twomey, Dick Allen, Kim D Blickenstaff and Richard P Valencia. View Insider Buying and Selling for Tandem Diabetes Care.

How do I buy shares of Tandem Diabetes Care?

Shares of TNDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Tandem Diabetes Care's stock price today?

One share of TNDM stock can currently be purchased for approximately $63.58.

How big of a company is Tandem Diabetes Care?

Tandem Diabetes Care has a market capitalization of $3.73 billion and generates $183.87 million in revenue each year. The medical device company earns $-122,610,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis. Tandem Diabetes Care employs 653 workers across the globe.View Additional Information About Tandem Diabetes Care.

What is Tandem Diabetes Care's official website?

The official website for Tandem Diabetes Care is http://www.tandemdiabetes.com/.

How can I contact Tandem Diabetes Care?

Tandem Diabetes Care's mailing address is 11075 ROSELLE STREET, San Diego CA, 92121. The medical device company can be reached via phone at 858-366-6900 or via email at [email protected]


MarketBeat Community Rating for Tandem Diabetes Care (NASDAQ TNDM)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  466 (Vote Outperform)
Underperform Votes:  454 (Vote Underperform)
Total Votes:  920
MarketBeat's community ratings are surveys of what our community members think about Tandem Diabetes Care and other stocks. Vote "Outperform" if you believe TNDM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TNDM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/19/2019 by MarketBeat.com Staff

Featured Article: What is a capital gain?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel